According to the Zhitong Finance App, Kangtai Biotech (300601.SZ) released its report for the third quarter of 2026. In the first three quarters, the company achieved revenue of 1,841 billion yuan, a year-on-year decrease of 10.79%. Net profit attributable to shareholders of listed companies was 95.3511 million yuan, an increase of 93.97% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 589.19 million yuan, an increase of 111.34% over the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.